2026
conference-abstract
OpenAlex
Laura Meili Linville, H. Wang, Jeanny B. Aragon-Ching
48 Background: The incidence of stage IV prostate cancer in the United States has risen over the past decade, possibly reflecting changes in PSA screening guidelines. Recent studies have also shown increasing implementation of active surveillance in the initial management of intermediate-risk …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Chaitra Shankar Ujjani, H. Wang, Catherine M. Broome, Ajay K. Gopal et autres
Background: Ibrutinib (I) and venetoclax (V) have modest single-agent activity in relapsed/refractory follicular lymphoma (FL) (Gopal A, JCO 2018; Davids M, JCO 2017). Preclinical data have shown synergy I and V (Kuo H, Mol Cancer Ther 2017). Based on these data, we …
Afrique du Sud, us
(code pays fourni par la source)
2022
article
OpenAlex
John F. Deeken, Prachi Kothiyal, H. Wang, Grace Jo et autres
us
(code pays fourni par la source)
2020
article
OpenAlex
Jeremy J. Mandia, H. Wang, Ranjani Padmanabhan, Z. Ferguson et autres
us
(code pays fourni par la source)
2020
article
OpenAlex
Jeremy J. Mandia, H. Wang, Ranjani Padmanabhan, Zak Ferguson et autres
us
(code pays fourni par la source)
2019
article
OpenAlex
Chaitra Shankar Ujjani, H. Wang, Lori Ann Leslie, Michael D. Johnson et autres
Background: Despite high response rates to front-line chemoimmunotherapy, patients with follicular lymphoma (FL) inevitably relapse and further treatment options are necessary. The BTK inhibitor, ibrutinib, has demonstrated an overall response rate (ORR) of 21% and median duration of response of 19 months …
us
(code pays fourni par la source)
2014
article
OpenAlex
Jennifer Ai-Lian Woo, L.N. Chen, H. Wang, J.S. Kim et autres
us
(code pays fourni par la source)